While the development of anti-vascular endothelial growth factor (anti-VEGF) as a therapy
for neovascular age-related macular degeneration (AMD) was a great success, the …

Among older adults, age-related macular degeneration (AMD) is a prevalent disabling
condition that begins as subtle visual disturbances and can progress to permanent loss of …

Current therapy for age-related macular degeneration (AMD) shows a dramatic change from
clinical practice a decade ago. While the first pharmacologic treatment, verteporfin …

Age-related macular degeneration (AMD) constitutes a prevalent, chronic, and progressive
retinal degenerative disease of the macula that affects elderly people and cause central …

Age-related macular degeneration (AMD) affects an estimated 14 million people worldwide,
and is the leading cause of severe, irreversible vision loss in individuals over the age of 50 …

Age-related macular degeneration (AMD) is the leading eye disease to cause visual
impairment in the elderly. Neovascular AMD is a type of advanced AMD that is characterized …

Treatment of the neovascular form of age-related macular degeneration (AMD) has been
revolutionized by the introduction of such agents as ranibizumab, bevacizumab, and …

Age-related macular degeneration (AMD) is the leading cause of severe vision loss in
individuals over the age of 50 years. Choroidal neovascularization (CNV) is the hallmark of …

TOPIC: Discuss the emerging therapies that could improve the treatment of neovascular age-
related macular degeneration (AMD). CLINICAL RELEVANCE: Current antiangiogenic …

Background Visual impairment in elderly people is a considerable health problem that
significantly affects quality of life of millions worldwide. The magnitude of this issue is …